Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
about
Modulatory effects of bortezomib on host immune cell functionsThe ubiquitin-proteasome system and cardiovascular diseaseExpert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaModified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.On to the road to degradation: atherosclerosis and the proteasomeStrategies to modulate immune responses: a new frontier for gene therapyDifferential effects of lactacystin on cytokine production in activated Jurkat cells and murine splenocytesProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsDeletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice.Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensPoor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myelomaA critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes.Global intron retention mediated gene regulation during CD4+ T cell activation.Old game, new players: Linking classical theories to new trends in transplant immunology.Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.Immunomodulatory effects of anti-angiogenic drugs.Green tea consumption: an alternative approach to managing oral lichen planus.Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.Can we change the disease biology of multiple myeloma?Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.Epigallocatechin-3-gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression.Severe refractory CIDP: a case series of 10 patients treated with bortezomib.Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.Human Bocavirus Type-1 Capsid Facilitates the Transduction of Ferret Airways by Adeno-Associated Virus Genomes.Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs.Ubiquitin-proteasome system inhibitors and AMPK regulation in hepatic cold ischaemia and reperfusion injury: possible mechanisms.High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.
P2860
Q26795618-B195DB8D-E87A-4A72-947A-27A8F3C560BEQ27021582-499AF7C9-E407-467D-A10B-60D72E949654Q33413142-5E91DDF2-ED8B-409D-82CA-70097673711EQ33415992-ECB473A9-ED2F-438C-BDA3-608BC314892AQ33554513-1B124217-8170-4A81-8ABA-7C87BE7F722EQ33713999-29D167C2-9472-4A4A-937B-8DFCF1C49D5CQ34024993-632A348F-32F4-4037-8016-E3611BFE4DD7Q34085747-0129EE0A-0BD1-446E-9922-04234665ABBFQ35778422-4AE7AFBD-4C53-424E-AF36-80F796CDFB5EQ36217025-A43767CA-E12F-4390-A0F8-DA593E6EC772Q36378038-1B725A84-7EA6-4EAD-8164-6567313F0508Q36544872-188AFFF3-EA7D-4BA9-AAE6-E98CF91D1AC0Q36735810-0D2ECF0A-0279-4F6F-9F32-601BC5B302F9Q36761803-07E7F508-EB5C-4F6B-BCA0-973FB080576BQ36984148-8E67C84C-C38F-4ECB-8359-90F6CCEA2F3BQ37211030-12ECB17A-4A03-4DF0-9276-EC43215A9281Q37662989-A417917E-47C2-413D-A7C2-E3BB8B2ED42FQ37671216-F3A9EBBD-1E61-41DD-B55A-A9CFC410BBC5Q37702765-394D72B2-7656-4909-9469-3134F73013C2Q37847051-52DEAF36-BB8F-49F8-8445-B826FF9E5284Q37982959-735E1703-9513-4394-88E0-DCF2577C4A6CQ38034270-7D52E5AD-074F-44BF-AA46-CAA1131A194BQ38062038-EF1200F3-F3F1-4571-9597-DF89279AA2CEQ38237657-3CB4C2D1-DB48-40BB-8990-E602B98609F3Q38264990-D1FE7A24-2AE0-4342-84C9-394B3F52684DQ38427697-7C9D42C3-3FA7-4A2E-B1FC-9574C33005A8Q39638928-BA784DF0-E4BF-4FE2-A153-57B10196F13CQ39865668-92B4AAC3-939A-4364-825F-22F29FE783B3Q40081746-11C3A24A-96B4-49A8-BD07-558F3B4F7543Q40150859-76663EF7-05E8-45BA-B0A3-028BD81349AFQ40207332-077F49AA-4D18-4464-8C29-ED36E24127DAQ40498974-E1D989B3-163D-46AC-983E-3EB62D61CBF9Q41057184-3CAD41D8-DF44-4D2E-9415-B488435A7E0FQ42174557-501445B4-EAF6-4130-9A12-BF2F46598AD0Q42256487-A9D4DFB6-90A0-49FF-9FB5-A81CB5E3ABBEQ42277364-3DC2C554-2481-4ADD-819C-E0715101D5D1Q42738022-75A4C757-73F0-42CE-9004-ECE290C31DA6Q43086070-D833B2E5-5DBD-471A-B62B-E6E5946465E2Q43152799-012055D5-93DC-4B36-A380-75839D6FE2EFQ44236379-A505BAEC-204D-4B7B-9D12-F6FE1D3120DE
P2860
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@ast
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@en
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@nl
type
label
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@ast
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@en
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@nl
prefLabel
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@ast
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@en
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@nl
P2093
P2860
P1433
P1476
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
@en
P2093
Carsten Berges
Cord Naujokat
Dominik Fuchs
Heinrich Haberstock
Mahmoud Sadeghi
Marion Miltz
Volker Daniel
P2860
P304
P356
10.1111/J.1365-2567.2007.02761.X
P577
2008-01-23T00:00:00Z